rank	doi	journal	publication_date	pubmed_id	title
0	10.1097/CJI.0000000000000385	Journal of immunotherapy (Hagerstown, Md. : 1997)	2021-08-19	34406158	Long-term Overall Survival and Predictors in Anti-PD-1-naive Melanoma Patients With Brain Metastases Treated With Immune Checkpoint Inhibitors in the Real-world Setting: A Multicohort Study.
1	10.1016/j.mcpro.2021.100133	Molecular & cellular proteomics : MCP	2021-08-16	34391888	Optimized Liquid and Gas Phase Fractionation Increases HLA-Peptidome Coverage for Primary Cell and Tissue Samples.
2	10.1136/jitc-2021-002447	Journal for immunotherapy of cancer	2021-07-25	34301809|29906252|27138582|29395863|31601568|30242316|24132639|28212060|31953313|30242306|26952546|26712084|32728392|24845630|29540345|25399552|32681519|32673417|27979383|28453692|28228726|32402160|29162153|31639039	CX-072 (pacmilimab), a Probody 
3	10.1136/jitc-2021-002446	Journal for immunotherapy of cancer	2021-07-25	34301808|30913028|23741070|32049290|24433434|32681519|30110194|31601568|30242316|29355075|24132639|29162153|26027431|32246002|24845630|28729151|31488176|29540345|30130720|29562145|31562796|31100038|23724867|32245016|32116716|31953313	CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study.
4	10.1038/s41586-021-03704-y|10.1038/s41568-019-0235-4|10.1038/s41591-018-0266-5|10.1038/s41586-018-0130-2|10.1038/nature22991|10.1038/s41587-019-0322-9|10.1038/s41591-020-01206-4|10.1038/nmeth.4380|10.1016/j.cell.2018.10.038|10.1038/s41591-019-0522-3|10.1016/j.cell.2020.05.017|10.1182/blood-2006-11-056168|10.1093/nar/gkaa796|10.1172/JCI73639|10.1158/0008-5472.CAN-18-0163|10.1038/s41467-018-05072-0|10.1038/s41590-019-0312-6|10.1016/j.immuni.2016.07.021|10.1038/nature19330|10.1016/j.immuni.2018.12.021|10.1038/nature24993|10.1016/j.immuni.2007.07.010|10.1038/s41586-019-1836-5|10.1126/science.abb9847|10.1016/j.cell.2020.09.015|10.1038/s41586-020-2056-8|10.1016/j.smim.2020.101437|10.1038/nri.2017.131|10.1016/j.cell.2019.05.031|10.1038/s41592-019-0619-0|10.1158/0008-5472.CAN-06-1450|10.4049/jimmunol.1103020|10.4049/jimmunol.0902047|10.1182/blood-2018-04-843763|10.1084/jem.180.1.347|10.1016/j.immuni.2017.02.007|10.1615/CritRevImmunol.v24.i4.40|10.1177/1087057108329453	Nature	2021-07-23	34290406	Phenotype, specificity and avidity of antitumour CD8
5	10.6004/jnccn.2021.0018	Journal of the National Comprehensive Cancer Network : JNCCN	2021-04-13	33845460	NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021.
6	10.1158/1078-0432.CCR-20-2790	Clinical cancer research : an official journal of the American Association for Cancer Research	2021-03-31	33782030	Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab ± Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer.
7	10.1002/cam4.3789	Cancer medicine	2021-03-17	33724703|28600969|31320640|23071856|27533633|23568491|29320474|27882345|27863258|28296713|21642685|28467829|27536065|30782616|28557599|25409260|25765070|26842708|26359337|22150006|12744608|20525992|30664638|27739435|18066592|27470968|25428359|26264378|25399552|16908931|28481359|26854966|10809223|23313955|28056206|30202085|27054074|22588877|23775962|27123562	Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade.
8	10.1007/s00262-021-02855-1|10.1001/jamaoncol.2015.0137|10.1038/s41598-019-50574-6|10.2217/imt-2017-0108|10.1200/JCO.2012.41.6750|10.1038/s41416-018-0155-1|10.1002/cncr.31629|10.1200/jco.2018.79.0006|10.1186/s40425-019-0805-8|10.1016/j.jtho.2018.06.004|10.1136/esmoopen-2018-000457|10.1038/s41571-020-0352-8|10.1186/s40425-015-0081-1|10.1001/jamaoncol.2018.0798|10.1001/jamanetworkopen.2019.2535|10.1038/nature14011|10.1111/cas.13226|10.3389/fmed.2018.00351|10.1200/JCO.2019.37.8_suppl.131|10.1186/s12967-018-1467-x|10.1158/1078-0432.ccr-18-2795|10.1111/cas.14363|10.1016/j.jdermsci.2016.12.019|10.1200/jco.18.02141|10.1186/s40425-019-0779-6|10.1158/1078-0432.ccr-15-2872|10.1046/j.1523-1747.2001.01316.x|10.1080/10739680701418416|10.3389/fonc.2018.00367|10.1038/31002|10.1084/jem.194.5.615|10.1159/000078582|10.1016/s1521-6616(03)00003-2|10.1084/jem.20121350|10.4062/biomolther.2014.102|10.1183/16000617.0012-2019|10.1016/j.jtho.2018.08.2035|10.1136/jitc-2020-000840|10.1001/jamaoncol.2018.3923|10.1172/JCI128654|10.1186/s40425-019-0583-3|10.1152/ajplung.00344.2017|10.1111/j.1365-2567.2009.03219.x|10.1200/JCO.2018.36.5_suppl.204|10.3892/ol.2020.11618|10.1093/ecco-jcc/jjv227|10.1200/jco.19.01674|10.1200/JCO.2020.38.5_suppl.89|10.1002/cncr.32966|10.1186/s12885-019-6138-7|10.1016/j.cyto.2015.11.025|10.2147/btt.s3543|10.1186/s40425-017-0300-z|10.1001/jamaoncol.2017.2925|10.1158/1078-0432.ccr-15-1136	Cancer immunology, immunotherapy : CII	2021-01-23	33481042|31575933|29067884|30377338|29975414|30125216|31730012|29935305|30964126|32546734|26380086|29800974|31050774|25428504|28266140|29642948|30409824|32086984|28069323|31216228|31801636|26957557|11348459|17952801|30250827|9624005|11535630|15237263|12584051|27098623|24821910|31694838|30267842|32554618|30242316|31310589|31014385|28860146|20070409|32565986|26783344|32567084|31664934|26687628|29162153|28975219|26446948	Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors.
9	10.1038/s41591-020-01206-4|10.1016/j.cell.2019.05.031	Nature medicine	2021-01-23	33479501|28678778|30568305|25837513|28678784|31358999|30803026|16424171|28111070|26449664|23008334|32497499|28060797|33020644|32610128|33064988|21216894|21205303|21430775|21307934|3167057|21221095|20644199|4383288|22539670|27737878|28893733|31959774|22912393|30283138|19414787|14530340|22544927|17440104|30150207|24385147|24832523|31114916|31341290|19002680|21047511|31495665|28978689	Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma.
10	10.1038/s41571-020-00460-2	Nature reviews. Clinical oncology	2021-01-22	33473220|30774998|30691374|23945592|31011208|27192170|32238575|30568303|30568305|24043743|26516200|27149842|24782321|25594174|26871470|26980598|25409260|26359337|26940869|25765070|26028255|30395155|30842677|29867230|30150660|26997480|22318521|27350335|28031159|30894752|30742119|29115304|28678778|28678784|4549796|29226910|29751996|31015635|24894089|32045313|28978689|28228285|31844290|26416257|17911588|19890126|25901682|25493333|24837101|31495665|31611696|32308001|32764681|29643231|24987109|29174843|30683863|31036766|23770567|31804810|32259744|29458962|28869761|18219309|23890070|20619696|16818737|21029957|26449178|23080391|6255921|31467405|29466754|5177508|25170049|26688350|30952804|21841802|31255505|28628092|30006565|31227543|31110315|25957682|30676822|17950003|22623779|27789795|28514453|27789799|28648661|27939672|30778252|30154266|30635237|26781939|10725753|11086036|9480979|31645760|31810883|20940398|15780993|18292535|10411927|28111070|25531942|18565862|24812403|28755541|23087058|29126798|27775706|26441961|31801070|30463850|20156971|32497499|30635355|29458967|33064988|30962585|29567706|31358999|24891321|29403468	Advances in the development of personalized neoantigen-based therapeutic cancer vaccines.
11	10.1016/j.kint.2020.12.015	Kidney international	2020-12-29	33359528|32027461|21401869|22830463|30516812|28076715|31206316|15905503|18784101|18212277|31896554|30992053|31562797|28889792|20925547|30798791|32042196|32588077|30016177|31672794|30125216|24662767|31206226|24730453|26962927|24493726|32043028|33102962|25891173|28835386|29863979|23818517|25838373|31624262	A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant.
12	10.1016/j.xcrm.2020.100141	Cell reports. Medicine	2020-12-10	33294862|32001676|24510963|33064988|22318521|26258412|20385014|29309059|29075258|22918931|25838375|23319654|26085931|31942075|17440104|32110781|20080641|17859590|26001779|25924071|29997287|32162785|26137399|31775882|17082316|30425105|24566718|29348598|29942309|30541882|29353553|29896449|26404496|29503570|25632034|32042196|24400004	Combined TCR Repertoire Profiles and Blood Cell Phenotypes Predict Melanoma Patient Response to Personalized Neoantigen Therapy plus Anti-PD-1.
13	10.1016/j.cell.2020.08.053	Cell	2020-10-17	33064988	A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer.
14	10.1158/1078-0432.CCR-20-1790	Clinical cancer research : an official journal of the American Association for Cancer Research	2020-10-09	33028595	Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial.
15	10.1002/cncr.32966	Cancer	2020-06-23	32567084|30845259|26380086|31043390|31053497|27687304|26030049|28945858|24240160|26783344|21546723|21746882|21605467|30431562|30871542|17120402|31575933|23292894|22393130|23359064|29401166|19031030|27358490|26558876|21790683|26159695|27903418|28068177|10896912|26633184|29043290|28368458|23945234|29975414|24357284|22155183|27266980|25891304|30131322|28163705|29958857|29487980|28970729|29123955|18594491|31356558|31014995|25912039|29230210|29113194|28288458|29320654|22614989|31800340|16497887|16143122|25773946|27140411	Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor-induced colitis.
16	10.1200/JOP.19.00672	JCO oncology practice	2020-05-14	32401685	Safety of Immune Checkpoint Inhibitors in Patients With Pre-Existing Inflammatory Bowel Disease and Microscopic Colitis.
17	10.1002/cncr.32883	Cancer	2020-04-23	32320048	Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study.
18	10.1634/theoncologist.2019-0659	The oncologist	2020-02-12	32043699|9973463|22658128|28643391|29293878|28932782|28961840|26962927|30459942|30190859|30126374|29140833|27502714|25858804|25962109|30413665|26752406|29023959|19889124|28076715|27614165|29705511|28315636|28761949|27777773|27529458|27932166|28384452|30603124|26988410|30107088|28228726|29198341|24493726|9049215|21694936|29028789|26951628|27987584|29257718|29215617|15816877|22045767|17911605|30347289|27771741|26082835|23818517|28719552	The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature.
19	10.6004/jnccn.2020.0007	Journal of the National Comprehensive Cancer Network : JNCCN	2020-02-06	32023525	NCCN Guidelines Insights: Uveal Melanoma, Version 1.2019.
20	10.1158/2159-8290.CD-19-0790	Cancer discovery	2020-01-25	31974169	Directing Traffic: How to Effectively Drive T Cells into Tumors.
21	10.1038/s41598-019-56943-5|10.1038/nature06884|10.3390/jpm2010001|10.3390/jpm6010013|10.1016/j.cell.2019.02.003|10.3390/jpm7040012|10.3390/jpm4020163|10.1038/nri.2017.131|10.1126/science.aaa4971|10.1093/intimm/dxw027|10.1016/j.molmed.2017.08.007|10.1126/science.aar7112|10.1038/s41586-018-0792-9|10.1038/nature22991|10.1038/s41586-018-0810-y|10.1126/science.aaa3828|10.1038/nature23003|10.1056/NEJMoa0810097|10.1158/1078-0432.CCR-07-1881|10.1007/s00251-008-0341-z|10.1038/nchembio.2318|10.1002/cbic.201300797|10.1039/c4sc03877k|10.1039/c6ob00208k|10.1002/cbic.201300796|10.1002/psc.804|10.1038/nprot.2007.454|10.1021/acscentsci.8b00098	Scientific reports	2020-01-22	31959774|18421352|25562699|30901547|25563222|29226910|27235694|28867556|29567706|30568305|28678778|30568303|25837513|28678784|19890126|18172268|19002680|28244989|24616257|29403637|24616230|17121420|18079725|29721534	Automated Flow Synthesis of Tumor Neoantigen Peptides for Personalized Immunotherapy.
22	10.1016/j.jtho.2019.12.109	Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	2019-12-25	31870883	Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies.
23	10.1016/j.clcc.2019.09.001	Clinical colorectal cancer	2019-12-10	31813769	Real-world Treatment Patterns and Clinical Outcomes Across Lines of Therapy in Patients With Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer.
24	10.1158/2326-6066.CIR-19-0545	Cancer immunology research	2019-11-09	31699709|9480979|15252201|17295916|21282551|12488431|23894722|16636134|23404408|17892846|22174453|25891173|21872627|16424890|25838373|28187290|17517626|17911588|20525992|15471553|29480817|20075244|24309609|15623618|10188055|18759926|24622688|25524312|11668506|25840693|28891423|25633712|12186971|23032745|20083398|18418403|25891304|29696308|29658430|23455713|30267032|28388966|26608912|15384929|10201913|12138174|20194765|18566444|24777970|17441676|24801836	Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma.
25	10.1186/s40425-019-0782-y	Journal for immunotherapy of cancer	2019-11-09	31699149|18789150|3576016|20525992|26725537|29153542|25190764|29110018|30170821|26452570|30191256|26505811|30238891|29562145|23475400|25443003|29135615|29736922|9842949|23446092|27988158|28570290|28734759|29188198|24388022|28013246|18600380|25838373	Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma.
26	10.1007/s10120-019-01021-y	Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association	2019-11-05	31679092	Correction to: Developing real-world comparators for clinical trials in chemotherapy-refractory patients with gastric cancer or gastroesophageal junction cancer.
27	10.1016/j.jtho.2019.10.004	Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	2019-10-21	31629915	Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort.
28	10.1007/s10120-019-01008-9	Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association	2019-09-25	31549264|24343171|27248626|29944008|26502403|28056124|25792290|29543932|23937356|27096309|26884585|21422403|29159410|30620402|27592805|26161282|30111974|27858180|30207593|28605939|28993052|28941466	Developing real-world comparators for clinical trials in chemotherapy-refractory patients with gastric cancer or gastroesophageal junction cancer.
29	10.1200/EDBK_238001	American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting	2019-05-18	31099621	An Update on Adoptive T-Cell Therapy and Neoantigen Vaccines.
30	10.3389/fonc.2019.00199	Frontiers in oncology	2019-04-16	30984622|15738534|15908648|16112300|1707746|19097774|22702482|25113773|25754329|25828526|26712903|27285122|27649551|28397821|28463153|28662869|29437535|29449659|29562148|29566262|30280658|30397353	Palliative Radiation Therapy for Vertebral Metastases and Metastatic Cord Compression in Patients Treated With Anti-PD-1 Therapy.
31	10.1186/s40425-019-0512-5	Journal for immunotherapy of cancer	2019-03-30	30922394|26930325|27622997|7327978|22777757|21098782|26882087|24572565|25409260|16843351|29033130|28213000|26086965|27742636|26136188|17351260|7632965|27162688|27475805|26849842|6829490|28506965|25034862|26341892|25239112|16389251|18280327|26997480|28069728|24285872|26676067|21330339|19837679|9508197|3558716|28396509|25468746|20046124|22762315|23743018|26115796|25891304|27799234|12859163|6805298|1244564|26900952|29449192|25891173|19460605|26992568|8477683	Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition.
32	10.1158/2159-8290.CD-18-1357	Cancer discovery	2019-03-14	30862723|30568305|27281205|28678784|26501954|27550819|25132836|23455713|28848055|25837513|29226910|27079802|28650338|29942093|30557521|15340416|28678778|25667273|25428506|29654146|27367184|27301722|25428505|24812273|30568303|30309915|28397821|25838375|28886381|25901682|29326431|28024156|26645196|28102259|30154192|27096321|23788581|25838374|27146699|25970248|28239469|18236040|28446615|25838373|23307859	Cancer Vaccines: Steering T Cells Down the Right Path to Eradicate Tumors.
33	10.1016/j.hoc.2019.01.001	Hematology/oncology clinics of North America	2019-03-06	30833004	Immunotherapy: An Old and New Modality for the Treatment of Cancer.
34	10.1016/j.hoc.2018.12.009	Hematology/oncology clinics of North America	2019-03-06	30832998	Intralesional Cancer Immunotherapies.
35	10.1002/cncr.31892	Cancer	2019-01-29	30690710	A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma.
36	10.1038/s41586-018-0792-9|10.1126/science.aaa4971|10.1038/nrc3670|10.1038/nri.2017.131|10.1038/nature22991|10.1126/science.aaa3828|10.1038/nature23003|10.1038/nature12213|10.1158/1078-0432.CCR-13-0551|10.1126/sciimmunol.aan8664|10.1182/blood-2018-04-843763|10.1016/j.ccell.2017.06.003|10.1016/j.immuni.2017.02.007|10.1093/neuonc/nox036.071|10.1038/bjc.2017.142|10.1093/neuonc/noq001|10.1016/j.bcp.2016.12.011|10.1093/neuonc/nov151|10.1158/1078-0432.CCR-17-1846|10.1200/JCO.2009.26.3541|10.1056/NEJMoa043331|10.1016/S1470-2045(15)00088-1|10.1007/s00251-008-0341-z|10.1186/gb-2011-12-1-r1|10.1038/nbt.1523|10.1038/nature09837|10.1038/nature09744|10.1093/bioinformatics/btr446|10.1038/ng.806|10.1038/nbt.1754|10.1002/humu.22771|10.1093/bioinformatics/btu169|10.1038/ng.2653|10.1038/351290a0|10.1016/j.jim.2010.10.011|10.1038/s41598-017-03855-x|10.1073/pnas.1423482112|10.1158/1078-0432.CCR-12-1182|10.1182/blood-2017-03-770719|10.1002/0471142727.mb0422s107|10.1038/nature20123|10.1186/gb-2009-10-3-r25|10.1186/1471-2105-12-323|10.1038/nmeth.3800|10.1186/1472-6750-11-80|10.1093/nar/gkr771|10.1016/S0022-2836(05)80360-2|10.1038/nmeth.3364|10.1038/nature12912	Nature	2018-12-21	30568305	Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial.
37	10.1200/JCO.2018.78.2276	Journal of clinical oncology : official journal of the American Society of Clinical Oncology	2018-12-18	30557521	T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028.
38	10.1016/j.ygyno.2018.11.017	Gynecologic oncology	2018-12-12	30522700	Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028.
39	10.1007/s11912-018-0738-2	Current oncology reports	2018-12-01	30498900|8120958|29443657|22343569|1396582|25901682|25858804|23676462|28678778|26511282|29628312|28889792|16284400|29658430|22318517|25765070|22658127|24812403|23637340|26309093|3893689|22581824|28024156|11568001|7543139|25837513|21892917|28596308|21436444|8596936|20179267|28678784|10561265|18250415|25594174|12391205|18055460|27760322|28121507|24907378|25428506|18457330|26181000|22318521|11015443|8558223|7884429|3496540|27959684|16293754|21263073|24782321|29226910|27528724|17056533|24043743|12773629|25428507|10685652|27714434|11331315|23890059|26027431|26028255|20818862|7553894|25409260|29358500|22237626|28891423|22658128|25403209|16757567	Transformation of Old Concepts for a New Era of Cancer Immunotherapy: Cytokine Therapy and Cancer Vaccines as Combination Partners of PD1/PD-L1 Inhibitors.
40	10.1016/j.ccell.2018.10.007	Cancer cell	2018-11-14	30423297|9430231|26901407|18832713|27528724|8770874|19304471|27501248|2784858|16688182|22581824|25765070|24778315|26516200|18173375|17400610|26389673|2124236|21508983|12660922|17395538|12752672|17873878|24667641|29241547|25428505|28279590|17932562|21173239|25083336|22118527|18545704|11244051|24089328|26205583|20536563|26027431|10851045|28397821|21333600|22172723|27498556|27192565|27698113|28954221|16888018|11568001|23922299|26137416|27789795|27525433	PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8
41	10.1016/j.cell.2018.09.006	Cell	2018-11-06	30388455|26198319|26383138|29195078|24836921|28723893|29232554|29101163|29539425|26645196|26780092|25838373|28187290|29301958|29033130|28650338|26359337|27533448|29993362|26193793|19261174|22544022|20160101|25822800|26997480|28783722|24984854|29608179|21816040|16199517|28018602|18216267|26359985|23104886|22419253|28813415|26027431|22460902|27124452	A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade.
42	10.1016/j.jaad.2018.06.045	Journal of the American Academy of Dermatology	2018-10-17	30322559	A comparison of skin cancer screening and treatment costs at a Massachusetts cancer center, 2008 versus 2013.
43	10.1126/science.aar3593	Science (New York, N.Y.)	2018-10-13	30309915|10447503|12717023|14963618|15899795|16413538|18211710|18245491|19451168|19906727|20644199|21703392|22300766|22318521|23396013|23644516|23724846|23890060|23945592|24113773|24626129|24633410|24657537|24714771|24987110|25143287|25319062|25409260|25428505|25594174|25765070|25891173|25891174|25970248|26028255|26359337|26454859|26899170|26940869|26952546|26997480|27148822|27247226|27268795|27552095|27671167|27788043|27863197|28123883|28251903|28397821|28596308|28650338|29132144|29951597	Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy.
44	10.1016/j.ijrobp.2018.09.010	International journal of radiation oncology, biology, physics	2018-09-19	30227198	The Impact of Radiation Therapy on Lymphocyte Count and Survival in Metastatic Cancer Patients Receiving PD-1 Immune Checkpoint Inhibitors.
45	10.1097/CMR.0000000000000509	Melanoma research	2018-09-14	30211813	Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma.
46	10.1007/s00262-018-2241-x	Cancer immunology, immunotherapy : CII	2018-09-08	30191256|20525992|25795410|26037941|22648554|27480103|25399551|24054424|26027431|29573941|27269740|25891173|24661650|26839346|22356324|21150923|21639808|27622997|26115796|25891304|28359784|30002157|28243579|26181250|20004617|26742998|28241198|26563354|28889792|25265492|28189914|24089443|25265494	Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies.
47	10.1182/blood-2018-04-843763	Blood	2018-08-29	30150207|15064769|28233802|8702849|24121927|28678778|29311380|24777245|23227083|11792386|24952902|1709722|26858965|28931605|24348479|23415222|11466353|21135507|8211163|19002680|29226910|11479225|26463711|16373502|28636589|25619506|26372948|21047511|27550819|12079556|24172704|28228285|26409284|16951205|26466571|18985154|24891321|21221095|19436741|28623251|28636592|25646416	A cloning and expression system to probe T-cell receptor specificity and assess functional avidity to neoantigens.
48	10.1200/JCO.2017.76.6212	Journal of clinical oncology : official journal of the American Society of Clinical Oncology	2018-08-16	30110194|28052061|27157491|23724867|20160101|29543932|28501092|28993052|28850174|27269741|2702835|28596308|14970275|27892511|25079317|19097774|29355075|27932067|26027431|26028255|28678668|29122777	CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.
49	10.1093/annonc/mdy232	Annals of oncology : official journal of the European Society for Medical Oncology	2018-07-12	29992241	Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study.
50	10.1158/1078-0432.CCR-17-3452	Clinical cancer research : an official journal of the American Association for Cancer Research	2018-03-22	29559561	Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer.
51	10.1038/nature25145	Nature	2018-03-16	29542692|28678778	Corrigendum: An immunogenic personal neoantigen vaccine for patients with melanoma.
52	10.1038/nrclinonc.2018.36	Nature reviews. Clinical oncology	2018-03-14	29532797|23743568|19934295|28271869|28592629|19097774|29341833|7459811	Immunotherapy: Immune-modified response criteria - an iterative learning process?
53	10.1002/cncr.31200	Cancer	2018-01-10	29313945	Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management.
54	10.18632/oncotarget.22583	Oncotarget	2018-01-02	29290936|25765070|27159395|28489510|27683556|23636398|25838375|28846956	PD-1 inhibitors in endometrial cancer.
55	10.1038/nri.2017.131	Nature reviews. Immunology	2017-12-12	29226910|19717467|25860605|11509172|26205340|25584002|12908518|26214521|19995538|28244989|25901682|27084742|11130078|28678778|28239469|21189474|19974799|23133825|25800770|26669718|1840703|24480625|22318517|25765070|22658127|24812403|27775706|27084738|19155470|28202532|24048065|14976262|23912587|27093365|21048000|28228279|25877890|27084740|28024156|22258609|20518717|1712030|8564842|25837513|25891304|23415222|27928025|17344846|15623607|28596308|25483644|24739759|28228285|15340416|20408898|25762141|20100959|15252201|22842478|26093618|23569326|8097319|18245491|22437939|18418403|25482239|28678784|25625927|23335921|27757559|22790179|25594174|23885823|25136133|28185916|25409260|27576783|25531942|23644516|24891321|4573839|23633484|15024047|9050879|26515495|25625926|28102259|24837101|21894173|27149842|25428506|24788102|22437871|23770567|26501954|27926855|18724357|26181000|22318521|15309328|24871131|24590637|24583799|28233802|22065672|25493333|27550819|23945592|25838374|12242449|3882219|12473578|24457417|24782321|7513441|26158218|26359337|25786696|10430624|24043743|17517626|25101225|21506644|23032745|12682289|11913069|20092022|25428507|1984929|7753172|27146699|25959818|23539594|22397650|24309663|26781939|25838375|25415283|24894089|25485616|9120389|23890059|27029192|26923002|28847868|26516200|26093657|24913717|26027431|28187290|26028255|12947071|8145819|20818862|19890126|11134207|27433843|12925849|23460534|27350335|25001465|8977634|22237626|22658128|17975151|9500607	Towards personalized, tumour-specific, therapeutic vaccines for cancer.
56	10.1158/2159-8290.CD-17-0833	Cancer discovery	2017-11-05	29101162|24819215|20160101|28292435|22437869|25858804|26546453|28963140|23172153|3964538|27346349|19910308|28404866|27301722|27092830|28397821|26645196|28052254|26598942|27093365|27539742|26091043|27687979|25891304|28819027|16509995|27699239|25667295|23420877|28723893|26787823|22437870|25944800|19095563|19581407|23633484|28356390|19208382|26918260|26536825|24948366|18379575|27229745|26359337|24138885|25201530|24227677|25013076|23778140|22186141|24444711|26398076|26997480|28187290|27124452|25606824|27912061|27951441|27332730|28886003	
57	10.1200/JCO.2017.74.5471	Journal of clinical oncology : official journal of the American Society of Clinical Oncology	2017-11-03	29095678	Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial.
58	10.1158/2326-6066.CIR-17-0208	Cancer immunology research	2017-10-29	29079654|23724867|28246107|22658127|25538262|25078147|26282644|25891304|24610577|68224|7018893|22437870|20525992|23724846|25891173|26186958|26115796|26181250|27571185|25751110|26027431|25605845|21088057	Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy.
59	10.1200/JCO.2017.74.8681	Journal of clinical oncology : official journal of the American Society of Clinical Oncology	2017-09-08	28880745	Reply to F. Tomao et al.
60	10.1200/JCO.2017.72.5069	Journal of clinical oncology : official journal of the American Society of Clinical Oncology	2017-08-17	28813164	Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study.
61	10.1186/s40425-017-0273-y	Journal for immunotherapy of cancer	2017-08-16	28807048|26412456|20160101|25562142|27939400|24586709|27451390|23676462|24089443|23169436|27796306|24062984|26406148|27592805|28121507|25399552|25527358|27718847|26712084|26279307|25795410|27979383|26115796|27718784|26028407|27745820|25550543|26997480|28187290|24502656|27433843|26970723|27207108	Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series.
62	10.1186/s40425-017-0259-9	Journal for immunotherapy of cancer	2017-07-19	28716097|27737878|19633580|19974799|19934295|19052742|25667295|20525992|21639810|19889297|19139884|27367184|20563267|27146699|22397654	Regression of multifocoal in transit melanoma metastases after palliative resection of dominant masses and 2 years after treatment with ipilimumab.
63	10.1038/nature22991	Nature	2017-07-06	28678778|27737878|25493333|22912393|12975468|18463140|21047511|24777245|24836921|28228285|21803805|21307934|25531942|25891173|26449664|28111070|25867923|25837513|19002680|22065672|25765070|19890126|8145819|8673703|25043048|21478889|28099864|24837101|24812403|24695405|24987109|19182786|24043743|21430775|27312342|1709722|21221095|25703262|25838375|27192170|25901682|21205303|23008334|27121950|22581179	An immunogenic personal neoantigen vaccine for patients with melanoma.
64	10.1159/000475715	Oncology	2017-06-12	28601879	Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care.
65	10.1158/1078-0432.CCR-17-0114	Clinical cancer research : an official journal of the American Association for Cancer Research	2017-06-09	28592629|23724867|10655437|21036632|25937524|20729419|24661292|22451534|23743568|19934295|17785570|12829678|23922022|26545842|19561260|23787800|24264883|23254265|19097774|24590637|25795410|24145345|23789698|24991412|26261262|27458299|28018599|27330803|26951310|20651182	Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions.
66	10.1007/s11060-017-2485-x	Journal of neuro-oncology	2017-05-21	28527005	Erratum to: Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge.
67	10.1200/JCO.2017.72.5952	Journal of clinical oncology : official journal of the American Society of Clinical Oncology	2017-05-11	28489510	Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study.
68	10.1016/j.ijrobp.2017.02.003	International journal of radiation oncology, biology, physics	2017-05-04	28463153	Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy.
69	10.1093/annonc/mdx029	Annals of oncology : official journal of the European Society for Medical Oncology	2017-04-30	28453692|18430910|25970248|27788043|25765070|22658127|27052656|22958581|19115209|24390348|25949860|9164216|25838373|23986400|25428503|25631445|26429982|27157491|22020783|26359337|25891174|26027431|22461641|25409260|26028255|23288508|8823332	Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal.
70	10.1158/2326-6066.CIR-16-0287	Cancer immunology research	2017-04-12	28396509|26168215|25970248|25428505|27092830|22658127|26645196|26794281|25944800|26380088|23724846|25399552|19097774|25891173|24590637|26359337|27185375|26883990|26997480|25409260|26822383|8537970|27433843	Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced Melanoma.
71	10.1158/2326-6066.CIR-16-0302	Cancer immunology research	2017-04-05	28373217	Diagnostic Comparison of CT Scans and Colonoscopy for Immune-Related Colitis in Ipilimumab-Treated Advanced Melanoma Patients.
72	10.1007/s10555-017-9665-1	Cancer metastasis reviews	2017-03-23	28326450	Erratum to: Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma.
73	10.1158/2326-6066.CIR-16-0237	Cancer immunology research	2017-03-02	28246107|18314434|20525992|21455150|21639810|22483544|22547592|22614989|22658127|22858559|22911755|23262440|23341990|23357570|23458760|24053120|24831977|25428503|25795410|25840693|25888611|25891173|26027431|26028407|26115796|26371282|26406148|26412456|26559582|26712084|26970723|27458307|27718784|27718847|27745820|27979383|28034081|3802833|7786990|9310563	Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients.
74	10.1186/s40425-017-0218-5	Journal for immunotherapy of cancer	2017-02-28	28239469|23724867|22327211|20160101|24695685|1907934|24586709|14502282|16283570|25317870|9778055|27301722|19299733|25970248|26473188|15701862|23307859|22318517|25765070|22658127|21364688|24048441|5980117|27298410|19934295|15920010|25891304|24657536|25838373|24367702|21251614|16887003|20924111|24958825|10077623|10224276|15254595|23527958|26858122|21830940|17710230|20525992|22134155|15728465|25693024|23724846|26014293|21639810|9738663|12594303|26755520|26595810|22318521|21193697|21559358|12379851|8847724|26442214|23550685|20826737|25838374|19706802|26371282|7855601|23460535|8405064|20501944|25754329|21074066|20156973|26359337|7816841|25891174|22184371|22186141|23465466|23536636|25369488|25838375|11444391|1547488|20680802|23291374|26027431|26028255|15879151|26337719|10811122|21287334|22397654|24838938|27626062|25524800|1460426|22326955|27437105|22658128|24177180	Combination immunotherapy: a road map.
75	10.1016/j.immuni.2017.02.001	Immunity	2017-02-24	28228279|14993899|17726526|19002680|19903103|20601955|21816040|22517427|22544022|22588877|22842478|23550210|23554566|23644516|23900783|24043743|24120142|24836576|24894089|25263564|25323844|25409260|25525252|25765070|25838373|26192918|26359337|26372948|26410082|26645196|26851183|26940869|26997480|27149842|27350335|27433843|27667683|27959684|28031159|28115009	Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma.
76	10.1007/s10555-017-9656-2	Cancer metastasis reviews	2017-02-10	28181070	Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma.
77	10.1158/1078-0432.CCR-16-2017	Clinical cancer research : an official journal of the American Association for Cancer Research	2016-11-18	27852700|25355519|25739673|26638776|25779941|23322298|27052656|24642661|24390348|26678214|26619122|25871546|8552665|25891304|2724350|27111033|23150707|26498363|23770567|25203374|25559415|23945592|25631445|4830803|26359337|23509304|25891174|22544022|26003801|26017449|20147967|24336570|8823332|25003289|17150185|24821878|23578724	Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell Carcinoma.
78	10.1002/cncr.30259	Cancer	2016-10-21	27533633|25428504|23724867|25970248|25428505|23838913|25034862|25765070|22658127|15651058|16291983|23861464|25809697|15042682|18798304|25891304|16908931|23724846|25399552|12789276|24460190|23620124|25891173|7670677|24590637|25795410|25559415|26115796|26359337|23467045|26027431|9781962|25409260|26028255|18043047|24913711|15577323	The efficacy of anti-PD-1 agents in acral and mucosal melanoma.
79	10.1002/cncr.30258	Cancer	2016-10-21	27533448|26358406|25428505|22658127|19375060|21083380|8199443|16401785|26848796|23913718|20525992|25409260|23724846|25399552|26086854|19078957|23861464|25761109|19097774|25891173|25795410|26115796|25428503|26359337|22614978|7848381|26028407|25891174|26027431|24938562|26028255|16258106	Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies.
80	10.1016/S1470-2045(16)30496-X	The Lancet. Oncology	2016-10-14	27733243|26412456|25860605|26952546|22184381|17340590|25733301|16773629|20460488|23827737|25845990|25838373|25482239|26406148|25399552|15856431|19097774|2189954|27269741|22370319|11001674|26028407|4074823|18818309|23419284	Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial.
81	10.1016/S1470-2045(16)30366-7	The Lancet. Oncology	2016-09-14	27622997|23724867|21212434|23942774|27092830|25891304|25667295|20525992|25399552|25891173|25795410|26115796|25713437|26027431	Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.
82	10.1158/1078-0432.CCR-16-1320	Clinical cancer research : an official journal of the American Association for Cancer Research	2016-08-19	27535979|26412456|26760924|23724867|25897158|20516446|26205737|25800770|25937524|26176400|25034862|22658127|26100356|25891304|21444868|25482239|25452452|26406148|20525992|23724846|25704439|26865455|25891173|24590637|25795410|26115796|26028407|26765102|25891174|24032382|26027431	PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course.
83	10.1186/s40425-016-0152-y	Journal for immunotherapy of cancer	2016-08-18	27532025|25415286|19587352|24695685|18684942|16283570|25918658|25034862|23734322|22491251|22124094|21357649|27085692|23770775|11209085|23913718|20525992|21930211|23045571|7584144|23724846|21639810|14595408|25761109|25891173|24590637|19650371|22271879|25901283|24778161|17569889|26027431|23341990|27084345|25705383|20410257	Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy.
84	10.1200/JCO.2016.68.1106	Journal of clinical oncology : official journal of the American Society of Clinical Oncology	2016-08-17	27528724|23724867|22683710|18400189|19826129|24778315|22172723|25765070|22658127|22581824|11568001|26206951|26406148|18545704|24188664|12165551|26309093|12773629|16609058|25510272|26027431|19890111|24089328|10946310	Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors.
85	10.1007/s11060-016-2196-8	Journal of neuro-oncology	2016-07-13	27401151|25399551|15075910|22180178|22356324|23051966|23233711|19801201|12960123|25265492|23460716|20818844|23489557|12751378|21041710|25690538|21639808|25184259|18854571|18235113|25079100|22608338|18631394|23213105|23020132|23645591	Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge.
86	10.1016/j.kint.2016.04.008	Kidney international	2016-06-11	27282937|24067875|19587352|15752251|26873574|15588223|26282644|25891304|19414839|22547592|24610577|25482239|16943303|26406148|20525992|18185501|7584144|24927897|10485649|26342047|8676074|15340098|26115796|24687600|22010388|26028407|26874776|23060594|23341990|19679669|25605845	Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors.
87	10.1016/S1470-2045(16)30098-5	The Lancet. Oncology	2016-06-09	27269741	Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.
88	10.1158/1078-0432.CCR-15-2709	Clinical cancer research : an official journal of the American Association for Cancer Research	2016-05-06	27146699	Talimogene Laherparepvec for the Treatment of Advanced Melanoma.
89	10.1186/s40425-016-0129-x	Journal for immunotherapy of cancer	2016-04-22	27099755|25428504|25428505|25765070|22658127|25891304|25838373|25667295|20525992|25693024|17227898|21639810|26755520|25891173|22124101|24838938	Tumor control with PD-1 inhibition in a patient with concurrent metastatic melanoma and renal cell carcinoma.
90	10.3978/j.issn.2305-5839.2015.10.17	Annals of translational medicine	2015-12-24	26697473|25399551|24194739|20551059|16801397|22693252|23307859|22658127|23095323|25265492|25891304|23306863|24958825|26216948|17186030|20818844|20525992|24476824|14702634|24251082|23020132	Combined BRAF and MEK inhibition in BRAF(V600E) mutant melanoma: a synergistic and potentially safe combination partner with immunotherapy.
91	10.1001/jamaoncol.2015.4368	JAMA oncology	2015-12-04	26633184	Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders.
92	10.1080/2162402X.2015.1046028	Oncoimmunology	2015-10-10	26451318|15701862|23421690|16636135|22560555|19934295|25083318|14967443|18713980|25667295|24563870|20525992|21802280|21639810|13042090|17590405|23036459|19706802|11504745|24831977|19349616|24399786|20334528|23291374|22397654|22702482	A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab.
93	10.3389/fonc.2015.00202	Frontiers in oncology	2015-10-07	26442214|23724867|12529460|24778276|16186184|18193223|10537366|19949018|15637262|23438382|22549946|18157142|15585754|9570538|15776005|25891304|12586633|17671171|15611243|9059333|19364969|23108136|17699863|16179869|8640769|8756616|23440426|18725522|17121902|20631075|17008531|25756799|21553145|10667560|16557261|19090009|22123319|17376891|12682289|24793239|22186141|20819923|11444391|8837607|17013089|20680802|26027431|21753853|22737608|20004943|24838938|23320019|15542432|11507079|21880788|9834220	Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data.
94	10.1186/s13148-015-0091-3	Clinical epigenetics	2015-07-30	26221190|12115352|18272813|23982524|23457546|21885763|21817016|23008312|22663011|25119042|23805382|12068308|24511108|24504448|25609585|12447372|22157888|23045699|24980573|22945644|25151357|24569915|25112956|20513808|24453001|22494115|12789284|20525992|21778364|22817889|23550210|20973930|16912270|25399552|25081754|22693592|23858473|21639808|17218268|24169492|19228619|21896958|24872541|25414302|25188246|23348506|24978641|22588877|25393105|24265153|24686846|20421734|24763540|24978188|18821855|23630074|22980977|24628946|24880940|24710217|25517746|15188009|23020132|24511111|24622842	Targeted next-generation sequencing reveals high frequency of mutations in epigenetic regulators across treatment-naïve patient melanomas.
95	10.1158/2326-6066.CIR-15-0102	Cancer immunology research	2015-06-24	26100356|17875755|23724867|7694363|25416723|1396582|11813820|23400564|23410907|25034862|22658127|19934295|22614989|25538262|22109345|25078147|22451534|23408334|24610577|20177110|18852719|25619164|12601214|8596936|23718569|23913718|21785048|20525992|25704439|21639810|25726730|11015443|24590637|18832811|3496540|22271879|22547608|19139884|23460165|12682289|19200680|25614822|23439861|21074064|24278787|24838938	Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab.
96	10.1158/2326-6066.CIR-15-0066	Cancer immunology research	2015-05-07	25943535|25559415|21639810|22451534|2984574|3141506|1460426|8171324|10430077|15833068|19097774|19903780|19934295|19639560|20651182|20525992|20818862|21108592|25369488	Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic Melanoma.
97	10.1056/NEJMoa1414428	The New England journal of medicine	2015-04-22	25891304|25399551|23724867|20160101|25287827|22382362|25428505|22658127|25265492|20525992|23414587|25399552|21639810|19097774|21639808|24508103|22123319|24240160|25265494|24714771|23020132	Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
98	10.18632/oncotarget.2980	Oncotarget	2015-02-17	25682878|25210016|11078491|23724867|24777248|24695685|24991413|22356324|24812408|25034862|22658127|19934295|23169436|22614989|23868869|23709751|21739672|23087408|22742884|25667295|21185705|18500231|10561265|25977344|20525992|18759926|11267960|24829752|21074069|22663011|19581407|23020132|23724846|25399552|21639810|22437870|24695951|7670677|23774827|24590637|18173375|21639808|22611421|22271879|24145345|22735384|22419253|20143434|23439861|23295794|24278787|22266112|17897837	PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma.
99	10.1158/2326-6066.CIR-14-0202	Cancer immunology research	2015-01-31	25633712|23032745|24445780|15068864|20194765|16670346|16056255|17625806|19660592|15840697|12138174|18566444|24777970|15064759|23086756|9892619|23110239|19435913|23085951|12488431|12900270|18927625|15623618|24739759|15252201|21872627|9918682|19074257|23885825|24083080|21933959|18799141|18682521|20693851|23205468|15229469|21061265|24622688|17517626|19114863|20563267|15454922|24127556|22795876|16838179|22246032|10555997	Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma.
100	10.1158/1078-0432.CCR-14-2353	Clinical cancer research : an official journal of the American Association for Cancer Research	2014-12-30	25538262|11244047|25187037|10449568|15634713|22138079|22658127|22614989|23471977|16224277|16710025|17982122|19165221|19498038|19639414|20585348|20525992|22456429|23400564|23724846|23779068|23806261|24610577|24695685|24451730|25369488|25078147|11478060	Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study.
101	10.1007/s40265-014-0315-4	Drugs	2014-11-22	25414119|14688025|21519015|22589270|24138302|21953275|24265154|20668238|16364920|21118963|22315332|22663011|22084396|21107320|18390968|21519026|12628188|22443084|24567366|12068308|19934286|24010577|23434733|22197931|19706763|16291983|16337795|23735655|16273091|15543157|23735514|22048237|20215549|7692235|21594619|23306863|23444215|19243303|23261356|22588879|11242034|17428555|19433088|23200175|20179705|20127139|16009947|17785355|24746704|8774885|22241789|17075039|17332304|20130576|23406027|23414587|21483012|27424159|21779498|21444680|21383288|14991899|19029981|21523318|17237274|21383284|18632602|19567590|2547513|23934108|15035987|22506516|12670889|12509763|8157000|24947927|15958551|19251651|7499206|20179232|9727023|18381570|18562239|20802351|22496205|23629727|11943707|21900390|24265153|22510884|10490027|19915144|21245089|22805292|21705440|18676837|20331454|20920162|23020132|23153539|12644542|1501884|22805291|22538770	The biology and clinical development of MEK inhibitors for cancer.
102	10.1200/JCO.2013.54.8115	Journal of clinical oncology : official journal of the American Society of Clinical Oncology	2014-10-01	25267741|12778055|17284525|16489096|21469128|22891158|22356324|22663011|14696973|16644914|12590137|22658127|17947650|22649126|17475886|19833906|2702835|18803412|18381073|17541593|23626745|20818844|20525992|9443633|23656629|14568261|20215530|21639810|21172893|7814155|21639808|20711474|11114299|20375921|21047225|9262252|19383330|16609006|23323154|20570888|19320736|17951401|22658128	Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma.
103	10.2147/DHPS.S39568	Drug, healthcare and patient safety	2014-07-16	25018652|23724867|20004617|22113612|24138302|24265154|20668238|22270052|20551059|24089443|22663011|21107320|23051966|22256804|22658127|12068308|24183461|16291983|23709751|22389471|24577748|11504744|23306863|15014028|22395615|20179705|17785355|21343559|22763439|20525992|20130576|21483012|14559875|21383288|14991899|21523318|23724846|21383284|21639810|23248257|7670677|24114739|12670889|24590637|21639808|24265152|24508103|20187100|23550685|3312689|22735384|21502504|24265155|12365954|11943707|21900390|24265153|20147741|22608338|19671877|22805292|22083257|20864406|20141835|23020132|12644542|21856766|22067401|21107323|22805291|22538770|14679157	New developments in the treatment of metastatic melanoma - role of dabrafenib-trametinib combination therapy.
104	10.1158/2326-6066.CIR-13-0227	Cancer immunology research	2014-06-05	24894089|15695408|16287085|15048111|16322791|7652577|7644523|15614045|11160356|8673703|11325844|24090147|10602881|10820291|23690473|21986107|10582700|11358829|22052568|18221540|23258224|8642260|1417196|22842478|12771180|23770567|2021952|23644516|19884534|21047511|17409267|1323878|1323877|21216894|21478437|10064075|15705910|9823325|15128789|24043743|24777245|9461441|12747754|16497972|9892612|12947071|9637538|12473578|16247014|22237626|16391015|11448900|9973436	HLA-binding properties of tumor neoepitopes in humans.
105	10.1016/j.hoc.2014.02.008	Hematology/oncology clinics of North America	2014-06-02	24880947	Vaccines and melanoma.
106	None	Voprosy onkologii	2013-11-23	24260888	[Immediate results of combined treatment for soft tissue sarcomas including intraoperative radiation therapy].
107	10.3389/fimmu.2013.00346	Frontiers in immunology	2013-11-07	24194739|23724867|23483066|15128788|11568005|20551059|22356324|17641062|22663011|21107320|16801397|22693252|11099416|23307859|22658127|21086108|18628967|22475929|21169256|22355009|23306863|18180378|17186030|20818844|22226204|19197294|22763439|20525992|21159663|21383288|23724846|21088259|21639810|22156613|23204132|23335087|11238627|20959481|21639808|18008004|19244105|10910920|21730023|17050671|22805292|17308088|14702634|16581970|21156289|23020132|22658128|21107323|22805291	Impact of MAPK Pathway Activation in BRAF(V600) Melanoma on T Cell and Dendritic Cell Function.
108	10.1517/14656566.2013.849244	Expert opinion on pharmacotherapy	2013-10-22	24138302	Kinase inhibitors and immune check-point blockade for the treatment of metastatic melanoma and advanced cancer: synergistic or antagonistic?
109	10.1158/1078-0432.CCR-13-0143	Clinical cancer research : an official journal of the American Association for Cancer Research	2013-10-04	24089443	CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
110	10.1002/cncr.28282	Cancer	2013-08-06	23913718|12218599|23439861|12750097|14578381|8540843|8635073|9508371|9591028|9820172|16258106|18569391|19078957|19654573|19671877|19934295|20004617|20143434|20525992|21880788|21833591|22077981|22805292|23226204|23211837|12373596	Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.
111	None	Vestnik khirurgii imeni I. I. Grekova	2013-07-03	23808238	[Results of combined treatment with intraoperative radial therapy of soft tissue sarcoma].
112	None	Klinicheskaia meditsina	2013-06-26	23789456	[Long-term results of combined treatment of soft tissue sarcoma with the use of intraoperative radiotherapy].
113	10.1634/theoncologist.2012-0464	The oncologist	2013-05-30	23716015|11891956|22180178|12068308|14679157|15042682|15577323|16291983|16908931|17122627|17372901|18066592|19006261|18798304|19296537|19381944|19549917|19671877|19934295|20004617|20133697|20525992|20082117|21471822|21639808|21639810|22382362	Ipilimumab for patients with advanced mucosal melanoma.
114	None	Oncology (Williston Park, N.Y.)	2013-05-15	25184259	Treatment for advanced melanoma: new drugs, new opportunities, new challenges.
115	10.1007/s11060-013-1127-1	Journal of neuro-oncology	2013-04-13	23579338|15020614|15051777|22356324|23051966|12507084|12068308|22820413|15234044|16291983|22188003|15169796|22456429|20823850|21639808|17538177|18792064|22608338|18841050|15861414|22454535|20372154|21295875|23036672	Vemurafenib and radiation therapy in melanoma brain metastases.
116	10.1200/JCO.2012.44.7888	Journal of clinical oncology : official journal of the American Society of Clinical Oncology	2013-04-10	23569304	Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
117	10.1097/CMR.0b013e32835f3d90	Melanoma research	2013-03-07	23462208	Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery.
118	10.3978/j.issn.2304-3865.2012.11.05	Chinese clinical oncology	2013-03-01	25841448	The B7-H1/PD-1 pathway in cancers associated with infections and inflammation: opportunities for therapeutic intervention.
119	10.1007/s00262-012-1389-z	Cancer immunology, immunotherapy : CII	2013-01-12	23306863	Inhibition of both BRAF and MEK in BRAF(V600E) mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties.
120	10.1200/JCO.2012.43.5966	Journal of clinical oncology : official journal of the American Society of Clinical Oncology	2012-12-19	23248257|17507627|22194965|22180178|22356324|22663011|21107320|18390968|18559533|12068308|16291983|21635872|22048237|20215549|1604065|20818844|16009947|21343559|19097774|21639808|22735384|20332327|21245089|22805292|21156289|21107323|22805291	Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.
121	10.1007/s00280-012-1995-7	Cancer chemotherapy and pharmacology	2012-10-16	23064957	Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial.
122	10.1007/s10637-012-9862-2	Investigational new drugs	2012-08-07	22864522|14571701|12618329|15143074|2702835|2212128|1522818|16234528|16774044|16787144|16966688|17145837|17096330|17869378|18473854|19934275|20351325|20525992|20818844|20808309|21152246|21642685|21639808|21639810|22472884|10561265|10561349|10623706|10655437|12359751|12592378|14770441	Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma.
123	10.1038/modpathol.2012.43	Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc	2012-03-20	22425909|719608|21647761|19132446|21953023|19604349|18941457|17058288|19553103|21741600|17327608|14530498|15240741|15254595|19117354|20525992|19966936|21054833|17371975|18413770|21151098|21258248|12020220|20570696|15494715|15671534|20207826|19917835|19915147|16977338|18004626|21316501|18313653|10071292|17675538	Immune response in melanoma: an in-depth analysis of the primary tumor and corresponding sentinel lymph node.
124	10.1159/000335000	Oncology	2012-01-25	22270052	Enrollment in clinical trials correlates with improved survival in metastatic melanoma.
125	10.2217/imt.10.99	Immunotherapy	2011-02-17	21322760|10910920|10955814|11238627|11312255|11443573|11568005|11698435|11861597|12130531|12052830|12154357|12407406|12544886|10202148|15542432|15591335|15657294|15454486|15585754|15572591|15756019|15778348|15776005|15746082|15940673|16177074|16179869|16237114|16151467|16507829|16461746|18794101|18927310|18848473|18981115|19005412|19074257|19190114|19197294|19276286|19244102|19276342|19277038|18841360|19390566|19464605|19538929|19761435|19741157|20061405|20060329|20060330|20304705|20406969|16670284|16723621|16757724|16801397|16838025|16873671|17121902|17182569|17215529|17215530|17277106|17277121|17513751|17579043|17376891|17671171|17699863|17724683|18192925|18227218|18316545|18180378|18421059|18270248|18453565|18326818|18310500|18337760|18492954|18650514|18510589|20573926|20013807|20551059|20530283|20616810|20525992|12577055|12631595|12531798|12586633|12805336|14688354|14688356|14504105|14976062|15024050|14715630|15268851|15190258|15286804|15100154|15466206|2568561|1721644|7854419|8756616|8837607|9059333|9834220|10072524|10201904|10537366|10561265	Small-molecule protein kinase inhibitors and their effects on the immune system: implications for cancer treatment.
126	10.1371/journal.pone.0015588	PloS one	2011-01-06	21206909|10561349|20818844|10655437|10945621|12068308|12873977|12873990|12960123|14500344|15208680|15466206|8939849|15781657|16291983|16424035|16507829|16731745|16880785|16908931|16966688|17215530|17384209|18235113|18287029|18421059|18445842|18458053|18532874|18650514|18510589|19188183|19349552|19917255|20130576|20179705|18751976|20372153|10623706	A phase II trial of sorafenib in metastatic melanoma with tissue correlates.
127	10.1016/j.soc.2010.10.001	Surgical oncology clinics of North America	2010-11-30	21111958	Surgical approach to primary cutaneous melanoma.
128	10.1634/theoncologist.2010-0067	The oncologist	2010-06-24	20571149|12068308|12209995|12417504|12454112|12508243|12542213|12744608|12925346|12943498|14522889|14522897|15034504|15262258|6026974|5763191|5477666|4554758|4853771|4137290|4528796|1143724|1096931|7468915|6164474|7306920|7096100|7128372|6961509|6744219|3978548|3744859|3747692|3813595|3580331|2440332|3419168|2765227|2317465|1698595|1989926|2055225|1612500|1404568|8302112|8169521|8174062|8041523|7977524|7851168|7560180|7589763|8567269|8933929|9005147|9194459|9195622|9338460|9421225|9663250|9724998|9781962|10496563|10506714|10506715|13149891|13585343|15625120|15651058|15839963|16291983|16317276|16908931|16966688|17235244|17349716|17372901|17659849|17972544|18066592|18376227|18421059|18427595|18568775|18510589|19047099|19128387|19496721|19525876|19718013|19917835|10561349|10620439|10623706|10745167|10764419|10775846|10840932|11129421|11395556|11504745|11555721|11592745|11606084|11733955|11891956|12054708	Mucosal melanomas: a case-based review of the literature.
129	10.1371/journal.pone.0008714	PloS one	2010-01-26	20098694|10655437|18780814|15091196|15151950|15457099|1970948|1673965|7997706|7654429|8523052|8999970|9013474|15735119|15756276|16278399|16314632|16586011|17594721|17606972|17606973|17606974|17457044|17968020|18296423|18755900|18644829|18446338|19075286|10799747	A phase II trial of the epothilone B analog ixabepilone (BMS-247550) in patients with metastatic melanoma.
130	10.1586/era.09.40	Expert review of anticancer therapy	2009-06-06	19496721	Novel therapeutics for melanoma.
131	10.1159/000219435	Chemotherapy	2009-05-20	19451711	Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.
132	10.1016/j.clim.2007.05.012	Clinical immunology (Orlando, Fla.)	2007-07-17	17632036|10201913|16612374|15965491|10657635|10725731|10779776|11254738|11466353|11560993|11602637|11890616|12200067|12242444|12464571|12690202|12969552|14647476|14707071|14980436|15134772|15357943|6332146|2125367|1825981|8096238|8097338|8476563|7753171|7595228|7594516|8810254|8992980|9491999|9521319|9743334|9743552|9927507|16339526|16257061|10520991	The secretory IFN-gamma response of single CD4 memory cells after activation on different antigen presenting cell types.
133	10.1016/j.jneuroim.2005.09.004	Journal of neuroimmunology	2005-11-01	16257061	The cytokine signature of MOG-specific CD4 cells in the EAE of C57BL/6 mice.
134	10.1016/j.cellimm.2005.09.002	Cellular immunology	2005-11-01	16256965	IL-2 absorption affects IFN-gamma and IL-5, but not IL-4 producing memory T cells in double color cytokine ELISPOT assays.
135	10.1016/j.cellimm.2005.05.003	Cellular immunology	2005-08-27	16122720	CD4+CD25+ regulatory T cells control the progression from periinsulitis to destructive insulitis in murine autoimmune diabetes.
136	10.1016/j.clim.2004.12.005	Clinical immunology (Orlando, Fla.)	2005-05-05	15870028	Islet-cell antigen-reactive T cells show different expansion rates and Th1/Th2 differentiation in type 1 diabetic patients and healthy controls.
137	10.1016/j.jaut.2004.03.009	Journal of autoimmunity	2004-07-09	15236752	Increased in vivo frequency of IA-2 peptide-reactive IFNgamma+/IL-4- T cells in type 1 diabetic subjects.
138	10.1023/B:JOCI.0000029120.77824.41	Journal of clinical immunology	2004-05-28	15163889|10479395|10725731|11172025|3309126|11927947|10868936|11473034|11994372|8666914|7694152|1967440|9084973|7860747|9153283|11978633|9795763|11460579|8570667|7682817|7525393|8666144|12531872|10330297|8958223|2443575|11927616|10325232|7911924|2069944|11290812|1377368|7722468|9625765|9620678|10470079|7561070|7590815|10677521|2205920|11040068|10027571|1705279|1706385|11160133|8232539|12392292|10415074|9421467|9862731	T cells recognize multiple GAD65 and proinsulin epitopes in human type 1 diabetes, suggesting determinant spreading.
139	10.1016/j.jim.2003.12.007	Journal of immunological methods	2004-02-26	14980436	CD28 costimulation enhances the sensitivity of the ELISPOT assay for detection of antigen-specific memory effector CD4 and CD8 cell populations in human diseases.
140	10.1002/dmrr.320	Diabetes/metabolism research and reviews	2002-10-25	12397579	Cytokine detection by ELISPOT: relevance for immunological studies in type 1 diabetes.
141	10.3949/ccjm.66.10.601	Cleveland Clinic journal of medicine	1999-12-22	10598364	How physicians can help create useful clinical practice guidelines.
142	10.1016/s0735-1097(98)00081-3	Journal of the American College of Cardiology	1998-05-15	9581725	Cost of cardiac care in the three years after coronary catheterization in a contained care system: critical determinants and implications.
143	None	Schweizerische Monatsschrift fur Zahnheilkunde = Revue mensuelle suisse d'odonto-stomatologie	1973-02-01	4510298	[The superior genial tubercles in totally edentulous patients].
